Table S1 – Univariate analysis of the association of the $sTXB_2$ levels with the clinical and hematologic features at Visit 2

Variable	***Standardized B***	***Univariate p***
Platelet Count	0.35	<0.0001
Leukocyte Count	0.13	0.046
Age at enrollment	-0.20	0.002
Female Sex	-0.21	0.198
JAK2 mutation	0.42	0.09
Body mass index	-0.01	0.55
Cytoreductive treatment	-0.73	<0.0001

Table S2. Characteristics of ET patients overall and according to the absence (no) or presence (yes) of cytoreductive drugs at randomization.

	[ALL] *n=243*	No *n=98*	Yes *n=145*	P overall
Sex:				0.044
Male	112 (46.1%)	37 (37.8%)	75 (51.7%)	
Female	131 (53.9%)	61 (62.2%)	70 (48.3%)	
Age at enrollment (years)	60.0 [51.0;67.0]	53.0 [45.0;59.0]	66.0 [57.0;69.0]	<0.001
Diagnosis (Years)	5.00 [2.00;10.0]	4.00 [2.00;9.00]	5.00 [3.00;10.0]	0.034
BMI (kg/m^2)	25.0 [22.9;27.3]	24.6 [21.9;26.6]	25.2 [23.0;28.1]	0.030
Leukocytes ($x10^9/L$)	7.00 [5.66;8.50]	7.77 [6.73;9.17]	6.41 [5.15;7.69]	<0.001
Hematocrit (%)	41.7 [39.2;44.3]	43.4 [40.5;45.1]	40.7 [38.4;43.6]	<0.001
Platelets ($x10^9/L$)	521 [422;641]	631 [524;776]	455 [391;536]	<0.001
TXB_2 (ng/ml)	19.0 [9.20;42.6]	37.1 [16.0;64.0]	14.0 [8.00;29.0]	<0.001
TXM (pg/mg creatinine)	428 [318;618]	407 [303;611]	438 [326;629]	0.294
JAK2-V617F,n (%)†				0.140
Wild Type	99 (40.7%)	34 (34.7%)	65 (44.8%)	
Mutated	143 (58.8%)	64 (65.3%)	79 (54.5%)	
'Missing'	1 (0.41%)	0 (0.00%)	1 (0.69%)	
CALR, n (%):				0.258
Type 1	19 (7.82%)	6 (6.12%)	13 (8.97%)	
Type 2	16 (6.58%)	4 (4.08%)	12 (8.28%)	
Other	93 (38.3%)	35 (35.7%)	58 (40.0%)	

	[ALL] *n=243*	No *n=98*	Yes *n=145*	P overall
'Missing'	115 (47.3%)	53 (54.1%)	62 (42.8%)	
MPL, n (%):				0.061
Wild Type	111 (45.7%)	36 (36.7%)	75 (51.7%)	
Mutated	6 (2.47%)	3 (3.06%)	3 (2.07%)	
Not determined	125 (51.4%)	59 (60.2%)	66 (45.5%)	
'Missing'	1 (0.41%)	0 (0.00%)	1 (0.69%)	
Microvascular symptoms				0.266
No	218 (89.7%)	91 (92.9%)	127 (87.6%)	
Yes	25 (10.3%)	7 (7.14%)	18 (12.4%)	
Previous thrombosis**:				0.088
No	234 (96.3%)	97 (99.0%)	137 (94.5%)	
Yes	9 (3.70%)	1 (1.02%)	8 (5.52%)	

Quantitative values are reported as median (interquartile range), unless otherwise indicated. Significant differences between the different groups were tested based on the Kruskal-Wallis test or chi-square test for continuous or discrete variables.

Abbreviations: BMI: body mass index; TX: thromboxane.

** Defined as any major thrombosis occurring within 2 years before diagnosis and at any time afterward .



Figure S1. Correlation between platelet count at visit 2 and visit 3. The plots depict the correlation of platelet counts (x10^9/L) at randomization visit 2 (V2) and at the end of the randomized treatment visit 3 (V3).